
Terremoto Biosciences: Leveraging lysine-based biotech for optimized medicine development.
Founded with the mission to revolutionize drug discovery and development, Terremoto Biosciences focuses on leveraging lysine-based covalent chemistry to create optimized small molecule medicines. The company aims to deliver superior therapeutic benefits through innovative biotechnology solutions, targeting a broad market within the pharmaceutical and healthcare sectors.
Terremoto Biosciences has attracted notable investors and industry experts, contributing to its rapid growth and development. Key achievements include significant advancements in covalent chemistry applications, positioning the company as a leader in next-generation medicine development. The overall impact of Terremoto Biosciences is marked by its potential to transform therapeutic outcomes and improve patient care on a global scale.

Totus Medicines
totusmedicines.com

Hyku

Reactive Biosciences
reactivebio.com

XLock Biosciences
xlockbio.com

Lysosomal Therapeutics
lysosomaltx.com

Walden Biosciences

Lykos Therapeutics
lykospbc.com

Actio Biosciences
actiobio.com

Stramsen Biotech

Kezar Life Sciences

Octant
octant.bio

Lumen Bioscience
lumen.bio

Kathera Bioscience
katherabio.com

Telis Bioscience
telisbio.com

KNOW Bio
knowbiollc.com

Bond Biosciences
bond.bio

Transparency Life Sciences
transparencyls.com

Hapten Sciences
haptensciences.com

ExoLytics
exolytics.com

Theracos
theracos.com
Companies similar to Terremoto Biosciences include Totus Medicines, Hyku, Reactive Biosciences and XLock Biosciences.
Terremoto Biosciences was founded in 2021.
Terremoto Biosciences' headquarters is located in South San Francisco, CA, US.
Terremoto Biosciences' most recent funding round was for $108M (USD) in April 2026.
As of Apr 15, 2026, Terremoto Biosciences has disclosed funding of $358M (USD).
Terremoto Biosciences has 41 employees as of Feb 5, 2024.